Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06492122 · ClinicalTrials.gov registry record · Phase 1

Study With [225Ac]Ac-FL-020 in mCRPC Participants

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Full-Life Technologies.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
9
Study locations

NCT06492122: Recruiting Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Full-Life Technologies.

NCT06492122 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Full-Life Technologies. The registered enrollment target is 50 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 9 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06492122, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Full-Life Technologies.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

Primary Outcome

RP2D

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG [225Ac]Ac-FL-020
  • DRUG Blood samples for PK
  • DRUG [111In]In-FL-020
  • PROCEDURE Blood and urine samples collection
  • PROCEDURE SPECT/CT images

Study Locations (9)

Other

  • Princess Alexandra Hospital - Brisbane
  • Genesiscare Murdoch - Murdoch
  • MacQuarie University Clinical Trial Unit - Sydney
  • Beijing Cancer Hospital - Beijing
  • Ankara Üniversitesi Tıp Fakültesi Cebeci Hastanesi Nükleer Tıp Anabilim Dalı - Ankara

California

  • City of Hope Medical Center - Duarte
  • Chao Family Comprehensive Cancer Center - Irvine
  • University of Stanford - Stanford

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-08-30
Est. Completion 2026-12
Phase Phase 1
Full-Life Technologies

1 total trials

What NCT06492122 shows while recruiting

NCT06492122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which [225Ac]Ac-FL-020 is the first listed.

NCT06492122 lists 9 locations in 3 states (Other, California, Virginia).

Frequently Asked Questions

What is clinical trial NCT06492122 about?

NCT06492122 is a clinical study titled "Study With [225Ac]Ac-FL-020 in mCRPC Participants". The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

What is the current status of trial NCT06492122?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-08-30. Estimated completion is 2026-12.

What conditions does trial NCT06492122 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06492122?

The interventions under investigation include: [225Ac]Ac-FL-020 (DRUG), Blood samples for PK (DRUG), [111In]In-FL-020 (DRUG), Blood and urine samples collection (PROCEDURE), SPECT/CT images (PROCEDURE).

Who is sponsoring clinical trial NCT06492122?

This trial is sponsored by Full-Life Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06492122 being conducted?

This trial has 9 study locations across California, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06492122's enrollment target sits among peer trials

50 43rd of 69 higher than 26 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06492122

Source: ClinicalTrials.gov NCT06492122, the US trial registry maintained by the National Library of Medicine. NCT06492122 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.